Primary Cells Market

Primary Cells Market by Origin (Human Primary Cells, Animal Primary Cells), Type (Hematopoietic, Dermatocytes, Gastrointestinal, Hepatocytes, Lung, Renal, Musculoskeletal, Heart), End User, Region - Global Forecast to 2025

Report Code: BT 6489 Sep, 2020, by marketsandmarkets.com

[179 Pages Report] The global primary cells market is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7%. Market growth is driven by the rising prevalence of cancer, increasing cancer research, rising investments in regenerative medicine research, rising demand for monoclonal antibodies, and rapid growth in the biotechnology and biopharmaceutical industries.

Primary Cells Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Primary Cells Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. With the World Health Organization (WHO) officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small startups, have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. According to the WHO, at present, there are 70 vaccine candidates under development, and three candidates are already being tested in human trials. The economic and social burden of the pandemic has prompted government bodies globally to increase support for vaccine development, which has led to an increase in the adoption rates of primary cells for COVID-19 research.

Market Dynamics

Driver: Increasing cancer research

Cancer, which has become the leading cause of death globally, accounted for 9.6 million deaths in 2018. The growth in the prevalence of this disease has resulted in a need to conduct extensive research for diagnosis and treatment; primary cells form an important part of this research. These cells are ideal models for cancer biomarker discovery and drug screening. They are also used to understand the biochemical pathways of cellular interactions. In cancer research, primary cells are often exposed to heavy radiation doses, chemicals, and viruses, which transform these cells into cancer cells through genetic mutations and the introduction of oncogenes. In this way, the molecular-level mechanism and cause of cancer, as well as the altered signaling pathways of cancerous cells, can be studied.

Opportunity: Advancing biomedical research using primary cells in 3D cultures

Primary cells are considered to be more biologically representative in comparison to cell lines owing to their very identical characteristics to the original donor tissue. Owing to this, it is becoming increasingly evident that primary cells in 3D cell cultures are capable of producing more biologically representative models of in vivo multicellular environments as compared to cell lines. The adoption of primary cells in 3D cultures is high due to their more accurate outcomes as compared to normal cell lines. For example, primary hepatocytes cells, when cultured as a monolayer on plastic, become undifferentiated and die within four days.

Restraint: Concerns regarding primary cell culture contamination

Primary cell culture contamination is one of the most common problems encountered in cell culture laboratories. The use of contaminated cells endangers cell physiology and often leads to incorrect results or causes the loss of unique cell lines. Contamination in cell cultures not only slows down cell metabolism but can also contaminate final products such as vaccines, which can destroy the entire batch. Owing to this, companies limit their investments in cell-based research and undertake alternative methods for drug screening.

“In 2019, human primary cells segment accounted for the largest share of the primary cells market, by origin”

Based on origin, the primary cells market is segmented into human and animal primary cells. The human primary cells segment accounted for the largest share in the primary cells market in 2019. The increasing adoption of human primary cells in developing novel cancer therapies and the rising funding for the R&D for cell therapies are the major factors driving the growth of this segment.

In 2019, hematopoietic cells segment accounted for the largest share in the market, by type”

Based on type, the primary cells market is segmented into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2019, the hematopoietic cells segment accounted for the largest market share. This can be attributed to the rising prevalence of blood cancer and the increasing number of stem cell research projects. Hematopoietic cells are used to understand the biochemical pathways of tumor cells and the efficacy of different drugs. As a result, this segment accounts for the largest market share.

 “North America is the largest regional market for primary cells”

The global primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the primary cells market. The growth in the North American primary cells market can be attributed to the increasing number of players launching new human primary cells for research, expansion of the pharmaceutical and biotechnology industries, growing focus on R&D, and increasing prevalence of cancer in the region.

Primary Cells Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the primary cells market (2020- 2025)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Origin, type, end user, and region

Geographies covered

North America, Europe, Asia Pacific, and Rest of the World

Companies covered

Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sΰrl (Switzerland), ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic International (France).

This report categorizes the primary cells market into the following segments and subsegments:

By Origin

  • Human Primary Cells
  • Animal Primary Cells

By Type

  • Hematopoietic Cells
  • Dermatocytes
  • Gastrointestinal Cells
  • Hepatocytes
    • Cryopreserved Hepatocytes
    • Fresh Hepatocytes
  • Lung Cells
  • Renal Cells
  • Heart Cells
  • Musculoskeletal Cells
  • Other Primary Cells

By End User

  • Life Science Research Companies
  • Research Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific 
    • Rest of the World

Recent Developments

  • In May 2020, BioIVT (US) introduced high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development.
  • In January 2020, Charles River Laboratories acquired HemaCare Corporation. This acquisition will aid in expanding Charles River’s scientific capabilities in the high-growth cell therapy sector.
  • In September 2018, Sekisui XenoTech, LLC. (US) added monkey and rodent hepatocytes to its patented CryostaX product line.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 19)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKETS COVERED
                 FIGURE 1 PRIMARY CELLS MARKET
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 REPORT COMPARISON WITH THE JULY 2018 EDITION
           1.6.1 SUMMARY OF CHANGES
           1.6.2 LIMITATIONS OF THE CURRENT EDITION

2 RESEARCH METHODOLOGY (Page No. - 23)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
        FIGURE 2 PRIMARY CELLS MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.2.2.1 Key data from primary sources
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                 FIGURE 4 PRIMARY CELLS MARKET: BOTTOM-UP APPROACH
           2.3.2 TOP-DOWN APPROACH
                 FIGURE 5 PRIMARY CELLS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
        FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 31)
  FIGURE 7 PRIMARY CELLS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
  FIGURE 8 PRIMARY CELLS MARKET, BY ORIGIN, 2020 VS. 2025 (USD MILLION)
  FIGURE 9 PRIMARY CELLS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
  FIGURE 10 PRIMARY CELLS MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 34)
    4.1 PRIMARY CELLS MARKET OVERVIEW
        FIGURE 11 INCREASING CANCER RESEARCH IS DRIVING THE GROWTH OF THE PRIMARY CELLS MARKET
    4.2 PRIMARY CELLS MARKET, BY ORIGIN, 2020 VS. 2025 (USD MILLION)
        FIGURE 12 HUMAN PRIMARY CELLS SEGMENT TO DOMINATE THE MARKET IN 2020
    4.3 PRIMARY CELLS MARKET SHARE, BY END USER, 2020 VS. 2025 (USD MILLION)
        FIGURE 13 LIFE SCIENCE RESEARCH COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE PRIMARY CELLS MARKET DURING THE FORECAST PERIOD
    4.4 PRIMARY CELLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
        FIGURE 14 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE PRIMARY CELLS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 37)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 15 PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing cancer research
                            TABLE 1 PROJECTED INCREASE IN THE NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
                            TABLE 2 RESEARCH FUNDING FOR NATIONAL CANCER INSTITUTE, 2015 VS. 2017 (USD MILLION)
                    5.2.1.2 Advantages of primary human cells over cell lines
                    5.2.1.3 Increasing demand for monoclonal antibodies
                    5.2.1.4 Rapid growth in the biotechnology and biopharmaceutical industries
                            FIGURE 16 GLOBAL PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2017–2024
                    5.2.1.5 Growing focus on personalized medicine
                            TABLE 3 GROWTH IN THE NUMBER OF PERSONALIZED MEDICATIONS, 2008–2016
                    5.2.1.6 Government investments for cell-based research
           5.2.2 RESTRAINTS
                    5.2.2.1 Concerns regarding primary cell culture contamination
                    5.2.2.2 Ethical concerns regarding research in cell biology
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Advancing biomedical research using primary cells in 3D cultures
    5.3 COVID-19 IMPACT ON THE PRIMARY CELLS MARKET
    5.4 PRICING ANALYSIS
        TABLE 4 PRICE OF PRIMARY CELLS (2020)
    5.5 VALUE CHAIN ANALYSIS
        FIGURE 17 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
    5.6 SUPPLY CHAIN ANALYSIS
        FIGURE 18 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.7 ECOSYSTEM ANALYSIS OF THE PRIMARY CELLS MARKET
        FIGURE 19 ECOSYSTEM ANALYSIS OF THE PRIMARY CELLS MARKET

6 PRIMARY CELLS MARKET, BY ORIGIN (Page No. - 50)
    6.1 INTRODUCTION
        TABLE 5 PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
    6.2 HUMAN PRIMARY CELLS
           6.2.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
                 TABLE 6 HUMAN PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
    6.3 ANIMAL PRIMARY CELLS
           6.3.1 RISING INVESTMENTS IN ANIMAL CELL RESEARCH TO PROPEL THE MARKET GROWTH
                 TABLE 7 ANIMAL PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)

7 PRIMARY CELLS MARKET, BY TYPE (Page No. - 54)
    7.1 INTRODUCTION
        TABLE 8 PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
    7.2 HEMATOPOIETIC CELLS
           7.2.1 INCREASING CANCER RESEARCH & FUNDING TO PROPEL THE MARKET GROWTH
                 TABLE 9 HEMATOPOIETIC CELLS, BY TYPE
                 TABLE 10 HEMATOPOIETIC CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 11 NORTH AMERICA: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 12 EUROPE: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 13 ASIA PACIFIC: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.3 DERMATOCYTES
           7.3.1 RISING PREVALENCE OF MELANOMA IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT
                 TABLE 14 DERMATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 15 NORTH AMERICA: DERMATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 16 EUROPE: DERMATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 17 ASIA PACIFIC: DERMATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.4 GASTROINTESTINAL CELLS
           7.4.1 INCREASING INCIDENCE OF STOMACH CANCER TO BOLSTER MARKET GROWTH
                 TABLE 18 GASTROINTESTINAL CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 19 NORTH AMERICA: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 20 EUROPE: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 21 ASIA PACIFIC: PRIMARY GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.5 HEPATOCYTES
        TABLE 22 GLOBAL LIVER DISORDER INCIDENCE
        TABLE 23 HEPATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION)
        TABLE 24 HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 25 NORTH AMERICA: HEPATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 26 EUROPE: HEPATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 27 ASIA PACIFIC: HEPATOCYTES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           7.5.1 CRYOPRESERVED HEPATOCYTES
                    7.5.1.1 Longer lifespan of cryopreserved hepatocytes than fresh hepatocytes to drive market growth
                            TABLE 28 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION)
           7.5.2 FRESH HEPATOCYTES
                    7.5.2.1 Stringent regulations and limited availability of fresh hepatocytes to limit market growth
                            TABLE 29 FRESH HEPATOCYTES MARKET, BY REGION, 2018–2025 (USD MILLION)
    7.6 LUNG CELLS
           7.6.1 INCREASING RATE OF LUNG CANCER & COPD TO DRIVE THE DEMAND FOR LUNG CELLS
                 TABLE 30 LUNG CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 31 NORTH AMERICA: LUNG CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 32 EUROPE: LUNG CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 33 ASIA PACIFIC: LUNG CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.7 RENAL CELLS
           7.7.1 LACK OF AVAILABILITY OF EFFECTIVE RENAL THERAPIES TO PROPEL MARKET GROWTH
                 TABLE 34 RENAL CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 35 NORTH AMERICA: RENAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 36 EUROPE: RENAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 37 ASIA PACIFIC: RENAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.8 HEART CELLS
           7.8.1 HIGH INCIDENCE OF CARDIOVASCULAR DISEASES IS SUPPORTING THE GROWTH OF THIS SEGMENT
                 TABLE 38 HEART CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 39 NORTH AMERICA: HEART CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 40 EUROPE: HEART CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 41 ASIA PACIFIC: HEART CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.9 MUSCULOSKELETAL CELLS
           7.9.1 RISING INCIDENCE OF MUSCULOSKELETAL DISORDERS TO PROPEL MARKET GROWTH
                 TABLE 42 MUSCULOSKELETAL CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 43 NORTH AMERICA: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 44 EUROPE: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 45 ASIA PACIFIC: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.10 OTHER PRIMARY CELLS
         TABLE 46 OTHER PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
         TABLE 47 NORTH AMERICA: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
         TABLE 48 EUROPE: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
         TABLE 49 ASIA PACIFIC: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

8 PRIMARY CELLS MARKET, BY END USER (Page No. - 76)
    8.1 INTRODUCTION
        TABLE 50 PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
    8.2 LIFE SCIENCE RESEARCH COMPANIES
           8.2.1 INCREASING INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE THE MARKET GROWTH
                 TABLE 51 PRIMARY CELLS MARKET FOR LIFE SCIENCE RESEARCH COMPANIES, BY REGION, 2018–2025 (USD MILLION)
    8.3 RESEARCH INSTITUTES
           8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH AND HIGH PREVALENCE OF CANCER ARE DRIVING MARKET GROWTH
                 TABLE 52 PRIMARY CELLS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION)

9 PRIMARY CELLS MARKET, BY REGION (Page No. - 80)
    9.1 INTRODUCTION
        TABLE 53 PRIMARY CELLS MARKET, BY REGION, 2018–2025 (USD MILLION)
    9.2 NORTH AMERICA
        FIGURE 20 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
        FIGURE 21 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT
        TABLE 54 NORTH AMERICA: PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 55 NORTH AMERICA: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
        TABLE 56 NORTH AMERICA: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 57 NORTH AMERICA: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 58 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.2.1 US
                    9.2.1.1 High R&D spending and growing support for stem cell research to drive market growth in the US
                            FIGURE 22 US: CANCER INCIDENCE & MORTALITY, 2012–2035
                            TABLE 59 US: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 60 US: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 61 US: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 62 US: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Presence of advanced R&D infrastructure to drive market growth
                            TABLE 63 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 64 CANADA: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 65 CANADA: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.3 EUROPE
        FIGURE 23 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
        TABLE 66 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 67 EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
        TABLE 68 EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 69 EUROPE: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 70 EUROPE: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.1 UK
                    9.3.1.1 Growth in the life sciences industry to drive market growth in the UK
                            TABLE 71 UK: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 72 UK: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 73 UK: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.2 GERMANY
                    9.3.2.1 Increasing life science research activities to support market growth
                            TABLE 74 GERMANY: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 75 GERMANY: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 76 GERMANY: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Robust biotechnology infrastructure in the country to support market growth
                            TABLE 77 FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 78 FRANCE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 79 FRANCE: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Increasing number of cell biology seminars and conferences to fuel the adoption of primary cells
                            TABLE 80 ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 81 ITALY: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 82 ITALY: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.5 REST OF EUROPE
                 TABLE 83 ROE: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                 TABLE 84 ROE: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 85 ROE: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.4 ASIA PACIFIC
        FIGURE 24 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
        FIGURE 25 ASIA PACIFIC: PRIMARY CELLS MARKET SNAPSHOT
        TABLE 86 APAC: PRIMARY CELLS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 87 APAC: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
        TABLE 88 APAC: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 89 APAC: HEPATOCYTES, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 90 APAC: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Growing focus on cancer therapeutics-related research to bolster market growth
                            TABLE 91 CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 92 CHINA: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 93 CHINA: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Government initiatives to propel market growth in Japan
                            TABLE 94 JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                            TABLE 95 JAPAN: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 96 JAPAN: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.3 REST OF ASIA PACIFIC
                 TABLE 97 ROAPAC: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
                 TABLE 98 ROAPAC: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 99 ROAPAC: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.5 REST OF THE WORLD
        TABLE 100 ROW: PRIMARY CELLS MARKET, BY ORIGIN, 2018–2025 (USD MILLION)
        TABLE 101 ROW: PRIMARY CELLS MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 102 ROW: HEPATOCYTES MARKET, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 103 ROW: PRIMARY CELLS MARKET, BY END USER, 2018–2025 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 110)
     10.1 OVERVIEW
          FIGURE 26 KEY DEVELOPMENTS IN THE PRIMARY CELLS MARKET (2017 TO 2020)
     10.2 MARKET SHARE ANALYSIS
          FIGURE 27 PRIMARY CELLS MARKET SHARE, BY KEY PLAYER (2019)
     10.3 COMPETITIVE SCENARIO
             10.3.1 PRODUCT LAUNCHES
                    TABLE 104 PRODUCT LAUNCHES
             10.3.2 AGREEMENTS
                    TABLE 105 AGREEMENTS
             10.3.3 EXPANSIONS
                    TABLE 106 EXPANSIONS
             10.3.4 PARTNERSHIPS
                    TABLE 107 PARTNERSHIPS
             10.3.5 ACQUISITIONS
                    TABLE 108 ACQUISITIONS

11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 116)
     11.1 COMPANY EVALUATION MATRIX DEFINITIONS AND METHODOLOGY
             11.1.1 VENDOR EXCLUSION CRITERIA
             11.1.2 STARS
             11.1.3 EMERGING LEADERS
             11.1.4 PERVASIVE PLAYERS
             11.1.5 PARTICIPANTS
                    FIGURE 28 PRIMARY CELLS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
     11.2 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2019)
             11.2.1 PROGRESSIVE COMPANIES
             11.2.2 STARTING BLOCKS
             11.2.3 RESPONSIVE COMPANIES
             11.2.4 DYNAMIC COMPANIES
                    FIGURE 29 PRIMARY CELLS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019
     11.3 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
             11.3.1 THERMO FISHER SCIENTIFIC, INC.
                    FIGURE 30 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
             11.3.2 MERCK KGAA
                    FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2019)
             11.3.3 LONZA
                    FIGURE 32 LONZA: COMPANY SNAPSHOT (2019)
             11.3.4 PROMOCELL GMBH
             11.3.5 CORNING INCORPORATED
                    FIGURE 33 CORNING INCORPORATED: COMPANY SNAPSHOT (2019)
             11.3.6 AMERICAN TYPE CULTURE COLLECTION (ATCC)
             11.3.7 CELL BIOLOGICS, INC.
             11.3.8 HEMACARE CORPORATION (A CHARLES RIVER LABORATORIES, INC. COMPANY)
                    FIGURE 34 CHARLES RIVER LABORATORIES, INC.: COMPANY SNAPSHOT (2019)
             11.3.9 ZENBIO, INC.
             11.3.10 STEM CELL TECHNOLOGIES, INC.
             11.3.11 ALLCELLS
             11.3.12 AXOL BIOSCIENCE LTD.
             11.3.13 IXCELLS BIOTECHNOLOGIES
             11.3.14 NEUROMICS
             11.3.15 STEMEXPRESS
             11.3.16 BIOIVT
             11.3.17 SCIENCELL RESEARCH LABORATORIES, INC.
             11.3.18 SEKISUI XENOTECH, LLC
             11.3.19 PPA RESEARCH GROUP, INC.
             11.3.20 CREATIVE BIOARRAY
             11.3.21 BPS BIOSCIENCE, INC.
             11.3.22 EPITHELIX SΐRL
             11.3.23 REACHBIO LLC
             11.3.24 ACCEGEN
             11.3.25 BIOPREDIC INTERNATIONAL

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 173)
     12.1 INSIGHTS FROM INDUSTRY EXPERTS
     12.2 DISCUSSION GUIDE
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.4 AVAILABLE CUSTOMIZATIONS
     12.5 RELATED REPORTS
     12.6 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the primary cells market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Primary Cells Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the primary cells market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the primary cells market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Primary Cells Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global primary cells market by origin, type, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, and opportunities)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as product launches, partnerships, expansions, and acquisitions in the primary cells market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

Primary cells market size and growth rate estimates for counties in Rest of Europe, the Rest of Asia Pacific, and the Rest of the World

Company profiles

Additional five company profiles of players operating in the primary cells market

COVID-19

Get in-depth analysis of the COVID-19 impact on the Primary Cells Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Primary Cells Market

Request For Special Pricing
Report Code
BT 6489
Published ON
Sep, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Primary Cells Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved